Market Overview
The global Chagas disease market reached US$ 268 million in 2023 and is expected to reach US$ 467 million by 2031, growing with a CAGR of 7.2% during the forecast period 2024-2031.
Chagas disease also called American trypanosomiasis, is a parasitic, systemic, and chronic disease caused by the protozoan Trypanosoma cruzi. It is primarily transmitted to humans by blood-sucking triatomine bugs, often called "kissing bugs"
This disease has two types one is the acute phase, symptoms may include fever, swollen lymph glands, headache, and a skin lesion or purplish swelling on the eyelid known as Romaña's sign. This phase usually lasts for about 4-8 weeks. The second one is the chronic phase, most infected people enter the chronic phase without any symptoms. However, 20-30% of infected individuals develop cardiac disorders, such as an enlarged heart, heart failure, altered heart rhythm, and cardiac arrest, or digestive complications, such as an enlarged esophagus or colon.
Market Scope
| Metrics | Details |
| CAGR | 7.2% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$ Mn) |
| Segments Covered | Type, Drugs, Route of administration, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Rising Prevalence of Chagas Disease
The demand for the global Chagas disease market is driven by multiple factors. One of the primary factors is the rising prevalence of Chagas disease globally. According to the World Health Organization (WHO), in April 2023, an estimated 6-7 million people worldwide are infected with Trypanosoma cruzi, the parasite that causes Chagas disease, leading to some 12,000 deaths every year and leaving some 75 million people at risk of infection.
Annual incidence is 30-40,000 cases, but in many countries, detection rates are low (less than 10% and often less than 1%) and people suffering from the disease often encounter significant barriers to diagnosis and adequate healthcare.
Moreover, government strategies such as awareness programs, innovative project launches, and ongoing research studies in the development of treatment for Chagas disease would drive this market growth. For instance, in April 2023, WHO aimed to focus on the awareness of the Chagas disease among people this year the focus is on increasing awareness of Chagas disease, and by providing access to crucial care and implementing disease surveillance, at the primary health care level.
Also, in August 2022, the CUIDA Chagas project launched its digital platforms aiming at increasing the visibility of Chagas disease and promoting its activities.
Similarly, in December 2022, Tulane University researchers are working on a new Chagas disease vaccine that prevents lasting heart damage, a long-term complication of the tropical disease.
Restraints
Factors such as the high cost of the treatment, lack of awareness & diagnosis of disease, lack of accessibility to medication in rural areas, limited treatment options, a small number of drug approvals, and shortage of health care professional are expected to hamper the market.
Segment Analysis
The global Chagas disease market is segmented based on type, drugs, route of administration, distribution channel, and region.
The benznidazole segment accounted for approximately 45.3% of the global Chagas disease market share
The benznidazole segment is expected to hold the largest market share over the forecast period. Benznidazole is the first drug ever approved by the U.S. FDA to treat Chagas disease, a dangerous parasitic disease that affects an estimated 6 to 8 million people worldwide. It is a nitroimidazole derivative that has been used for the treatment of Chagas disease for several decades.
Benznidazole works by inhibiting the replication of Trypanosoma cruzi, the parasite that causes Chagas disease. The drug is effective in treating early-stage Chagas disease, but it is less effective in treating advanced cases of the disease.
Moreover, the rising number of clinical trials and combination therapy helps to drive this segment's growth in the market. For instance, in April 2023, Novartis Pharmaceuticals announced a study of phase 4 clinical trials for Enalapril and Sacubitril/valsartan. Additionally, the study aims to determine if sacubitril/valsartan leads to a more pronounced reduction in the levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) compared to baseline, specifically at the 12-week mark, in individuals with HF characterized by reduced ejection fraction (HFrEF) originating from chronic Chagas cardiomyopathy (CCC).
According to the Frontiers research publication in July 2022, stated that drug repurposing and combination therapy have been proposed as cost-effective strategies to improve Chagas disease treatment. The Miltefosine and Benznidazole combination improves anti-Trypanosoma cruzi in vitro and in vivo efficacy.
Geographical Analysis
North America accounted for approximately 41.2% of the global Chagas disease market share
North America region is expected to hold the largest market share over the forecast period. Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. Chagas disease is considered a neglected tropical disease. It is endemic in 21 countries in the Americas, although the migration of infected people can transport the disease to non-endemic countries of America and the world.
The rise in the number of Chagas disease cases will be the driving factor of the market in this region. For instance, according to the Pan American Health Organization, It is estimated that, in the Americas, Chagas disease shows an annual incidence of 30,000 new cases on average, 12,000 deaths per year, and approximately 9,000 newborns become infected during gestation. It is estimated that around 70 million people in the Americas live in exposure areas and are at risk of contracting this disease.
Moreover, in this region, key players' strategies such as partnerships and collaboration, well-established healthcare infrastructure, and major players' focus on research and developments would propel this market growth. For instance, in June 2022, The Pan American Health Organization (PAHO) and Unitaid launched a five-year, US$ 2.6 million partnership to scale up regional and national efforts to eliminate mother-to-child transmission of Chagas disease.
Also, in September 2022, Researchers from the University of Georgia discovered a potential treatment for Chagas disease, marking the first medication with a promise to successfully and safely target the parasitic infection in over 50 years. Human clinical trials of the drug, an antiparasitic compound known as AN15368, will hopefully begin in the next few years.
Market Segmentation
By Type
- Acute Chagas Disease
- Chronic Chagas Disease
By Drugs
- Benznidazole
- Nifurtimox
- Others
By Route of administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- The Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the Chagas disease market include Bayer AG, Novartis AG, Laboratorio Elea Phoenix, Maprimed, Nortec Quimica SA, Upsher-Smith Laboratories, Inc., Merck and Co., ChemFish Tokyo Co., Ltd., Anant Pharmaceuticals Pvt. Ltd., and InBios International Inc.
Key Developments
- In February 2024, The Healthy Brazil program was announced in partnership with the World Health Organization (WHO). The federal government launched a public policy to try to eliminate, as a public health problem, or reduce the incidence of 14 diseases that mainly affect populations in situations of social vulnerability, such as malaria, Chagas disease, HIV, and tuberculosis.
- In January 2024, a DNDi clinical trial for the treatment of Chagas disease carried out in Spain with a mostly Latin American population showed that the drug fexinidazole was well tolerated by patients in low doses, although it was not effective in the sustained elimination of the parasite Trypanosoma cruzi, which causes the disease.
- In April 2023, Kephera Diagnostics announced World Chagas Day, that it will be launching testing for Chagas disease through its CLIA-certified. Kephera will offer two tests – an FDA-approved ELISA and a new, multiplex test for Chagas disease – both of which detect antibodies to the parasitic agent that causes the disease.
Why Purchase the Report?
- To visualize the global Chagas disease market segmentation based on type, drugs, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of global Chagas disease market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The global Chagas disease market report would provide approximately 70 tables, 61 figures, and 183 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
